Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.
Standard
Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. / Gallina, Andrea; Nazareno, Suardi; Montorsi, Francesco; Capitanio, Umberto; Jeldres, Claudio; Saad, Fred; Graefen, Markus; Shariat, Shahrokh F; Widmer, Hugues; Arjane, Philippe; Péloquin, François; Perrotte, Paul; Karakiewicz, Pierre I.
In: INT J CANCER, Vol. 123, No. 3, 3, 2008, p. 647-652.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men.
AU - Gallina, Andrea
AU - Nazareno, Suardi
AU - Montorsi, Francesco
AU - Capitanio, Umberto
AU - Jeldres, Claudio
AU - Saad, Fred
AU - Graefen, Markus
AU - Shariat, Shahrokh F
AU - Widmer, Hugues
AU - Arjane, Philippe
AU - Péloquin, François
AU - Perrotte, Paul
AU - Karakiewicz, Pierre I
PY - 2008
Y1 - 2008
N2 - Trans-rectal ultrasound guided biopsy of the prostate represents the diagnostic standard for prostate cancer, but its mortality rate has never been examined. We performed a population-based study of 120-day mortality after prostate biopsy in 22,175 patients, who underwent prostate biopsy between 1989 and 2000. The control group consisted of 1,778 men aged 65-85 years (median 69.5), who did not undergo a biopsy. Univariable and multivariable logistic regression analyses were performed in 11,087 of 22,175 (50%) men subjected to prostate biopsy, to identify predictors of 120-day mortality. Variables were age at biopsy, baseline Charlson comorbidity index and cumulative number of biopsy procedures. We externally validated the model's predictors in the remaining 50% of men. Overall 120-day mortality after biopsy was 1.3% versus 0.3% (p <0.001) in the control group. Of men aged <or = 60 years, 0.2% died within 120 days versus 2.5% aged 76-80. Zero Charlson comorbidity score yielded 0.7% mortality versus 2.2%, if 3-4. First ever biopsy procedures carried a higher mortality risk than subsequent procedures (1.4 vs. 0.8 vs. 0.6%). In the multivariable model, first ever biopsy, increasing age and comorbidity predicted higher mortality. Overall, the model's variables were 79% accurate in predicting the probability of 120-day mortality after biopsy. In conclusion, our data suggest that prostate biopsy might predispose to higher mortality rate. The certainty of this association remains to be proven.
AB - Trans-rectal ultrasound guided biopsy of the prostate represents the diagnostic standard for prostate cancer, but its mortality rate has never been examined. We performed a population-based study of 120-day mortality after prostate biopsy in 22,175 patients, who underwent prostate biopsy between 1989 and 2000. The control group consisted of 1,778 men aged 65-85 years (median 69.5), who did not undergo a biopsy. Univariable and multivariable logistic regression analyses were performed in 11,087 of 22,175 (50%) men subjected to prostate biopsy, to identify predictors of 120-day mortality. Variables were age at biopsy, baseline Charlson comorbidity index and cumulative number of biopsy procedures. We externally validated the model's predictors in the remaining 50% of men. Overall 120-day mortality after biopsy was 1.3% versus 0.3% (p <0.001) in the control group. Of men aged <or = 60 years, 0.2% died within 120 days versus 2.5% aged 76-80. Zero Charlson comorbidity score yielded 0.7% mortality versus 2.2%, if 3-4. First ever biopsy procedures carried a higher mortality risk than subsequent procedures (1.4 vs. 0.8 vs. 0.6%). In the multivariable model, first ever biopsy, increasing age and comorbidity predicted higher mortality. Overall, the model's variables were 79% accurate in predicting the probability of 120-day mortality after biopsy. In conclusion, our data suggest that prostate biopsy might predispose to higher mortality rate. The certainty of this association remains to be proven.
M3 - SCORING: Zeitschriftenaufsatz
VL - 123
SP - 647
EP - 652
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 3
M1 - 3
ER -